Reported 5 months ago
Eli Lilly announced a significant increase in its investment by over $5 billion to expand a manufacturing site in Indiana to produce more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The company expects production to start at the new plant near Indianapolis by the end of 2026, with plans to ramp up production through 2028. Analysts predict that these drugs could generate over $30 billion in combined annual sales for Eli Lilly.
Source: YAHOO